Oxford Performance Materials
South Windsor, US · Founded 2011 · Delaware corporation
Oxford Performance Materials develops additive manufacturing (3D printing) technology and high-performance PEKK thermoplastics and coatings. Its products serve medical device applications, such as surgical implants via its OsteoFab platform, and industrial hardware markets through its OXFAB platform.
Advanced ManufacturingMedical DevicesNew Materials
Founders & leadership
SD
Scott DeFeliceExecutive Officer, Director
JD
Jordan DeFeliceExecutive Officer, Director
PM
Paul MartinExecutive Officer, Director
SZ
Severine ZygmontExecutive Officer, Director
AD
Anthony DeCarmineExecutive Officer
CC
Christopher CodeanneExecutive Officer
JS
Jacqueline SymingtonExecutive Officer
MF
Marc FasteauDirector
RF
Robert FiondellaDirector
AE
Amy EvansDirector
Competitors · 5
by search overlapMapquest12 shared keywordsProvider of geographical information systems and services; acquired by America Online.
BBB10 shared keywords
Globus Medical7 shared keywordsGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.
3Dprintingindustry6 shared keywords
Sparta Biomedical6 shared keywordsSparta Biomedical develops chemically engineered cartilage implants built on its Hyalos hydrogel platform, including Karthyx, an MTP hemiarthroplasty device that combines the cartilage-mimicking hydrogel with a titanium fixation technology. The company targets treatment of joint cartilage degeneration and osteoarthritis through cartilage-like implants for joints such as the great toe.
Companies competing with Oxford Performance Materials for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$355KraisedJul 2025 · 7 investors · OtherRule 506(b)
▶$355KraisedJul 2025 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jordan DeFeliceExecutive Officer, Director
- Marc FasteauDirector
- Robert FiondellaDirector
- Scott DeFeliceExecutive Officer, Director
- Amy EvansDirector
- Offering amount
- $5M
- Amount sold
- $355K
- Minimum investment
- $25K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.8MraisedFeb 2017 · 22 investors · OtherRule 506(b)
▶$10.8MraisedFeb 2017 · 22 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Marc FasteauDirector
- Lawrence VarholakExecutive Officer
- Christopher CodeanneExecutive Officer, Director
- Scott F DeFeliceExecutive Officer, Director
- Robert FiondellaDirector
- Severine ZygmontExecutive Officer, Director
- Brett SchneiderDirector
- Offering amount
- $10.8M
- Amount sold
- $10.8M
- Minimum investment
- $1
- Sales commissions
- $350K
- Placement agents
- Barclays Capital Inc., NewCap Partners Inc.
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.8MraisedJun 2016 · 6 investors · OtherRule 506(b)
▶$15.8MraisedJun 2016 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence VarholakExecutive Officer
- Scott F DeFeliceExecutive Officer, Director
- Severine ZygmontExecutive Officer, Director
- Christopher CodeanneExecutive Officer, Director
- Brett SchneiderDirector
- Offering amount
- $15.8M
- Amount sold
- $15.8M
- Minimum investment
- $1
- Sales commissions
- $255K
- Proceeds to insiders
- $800K
- Placement agents
- NewCap Partners Inc.
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedOct 2015 · 23 investors · OtherRule 506(b)
▶$5.4MraisedOct 2015 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Paul MartinExecutive Officer, Director
- Severine ZygmontExecutive Officer, Director
- Anthony DeCarmineExecutive Officer
- Christopher CodeanneExecutive Officer
- Jacqueline SymingtonExecutive Officer
- Scott F DeFeliceExecutive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- Minimum investment
- $10K
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $202.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.